Acrivastine
| 證據等級: L5 | 預測適應症: 6 個 |
目錄
Acrivastine: From Allergic Rhinitis to Allergic Urticaria
One-Sentence Summary
Acrivastine is a short-acting, second-generation, non-sedating histamine H1-receptor antagonist (a triprolidine derivative), documented in the published literature for the treatment of allergic rhinitis, chronic urticaria, and related allergic dermatoses. The TxGNN model predicts it may be effective for Allergic Urticaria, with 0 registered clinical trials and 9 published literature references currently supporting this direction. Evidence includes a double-blind randomised placebo-controlled trial and a systematic comparative review, providing a reasonable basis for a conditional proceed recommendation — though all supporting literature predates 2002 and formal UK regulatory status requires verification.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not registered in the current UK regulatory dataset; literature establishes use in allergic rhinitis and chronic urticaria (PMID 1715267) |
| Predicted New Indication | Allergic Urticaria |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L2 |
| UK Market Status | Not identified in current dataset — possible data collection gap; independent MHRA verification required |
| Number of Marketing Authorisations | 0 (per current dataset) |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in this Evidence Pack. However, based on the published literature, acrivastine is a competitive histamine H1-receptor antagonist. It selectively blocks H1 receptors on dermal mast cells and basophils, directly interrupting the histamine-mediated wheal-and-flare cascade that is central to the pathophysiology of urticaria. Its short duration of action (requiring three-times-daily dosing) and low CNS penetration distinguish it from first-generation antihistamines such as chlorphenamine, making it better tolerated in terms of sedation and anticholinergic side effects.
The mechanistic link between H1 receptor antagonism and allergic urticaria is direct and pharmacologically well-founded. In IgE-mediated allergic urticaria, antigen cross-linking of IgE on mast cell surfaces triggers degranulation and histamine release; this histamine then binds H1 receptors on cutaneous nerve endings and post-capillary venules, producing pruritus, erythema, and oedema. Acrivastine’s competitive blockade at H1 receptors therefore targets the terminal effector mechanism of the condition. Multiple comparative reviews and clinical trials published between 1988 and 2001 position non-sedating antihistamines including acrivastine as first-line therapy for chronic idiopathic urticaria.
The TxGNN prediction score of 99.99% is consistent with the drug’s established pharmacological class and the known relationship between H1 antagonism and urticaria. Rather than representing a novel repurposing discovery, this prediction represents a TxGNN-validated indication with strong mechanistic and clinical literature support. The principal clinical value in a UK context lies in confirming regulatory status and ensuring this agent is appropriately positioned within the formulary landscape alongside more recently evaluated antihistamines.
Clinical Trial Evidence
Currently no related clinical trials registered on ClinicalTrials.gov, the WHO ICTRP, or European clinical trial registers (EU CTR / ISRCTN).
No registered trials were identified for acrivastine in allergic urticaria. Available evidence derives entirely from published literature, including at least one prospective double-blind randomised placebo-controlled trial (see below).
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 9951950 | 1999 | Systematic Comparative Review | Drugs | Evaluated 10 second-generation antihistamines including acrivastine; confirms H1 antagonist class efficacy in urticaria and allergic rhinitis with substantially reduced sedation and anticholinergic adverse effects versus first-generation agents |
| 7911009 | 1994 | Double-blind RCT | Allergy | Acrivastine 8 mg single dose significantly suppressed histamine- and allergen-induced wheal response in skin prick tests within 15–30 min versus placebo; randomised crossover design in 10 pollen-allergic subjects |
| 1715267 | 1991 | Pharmacological Review | Drugs | Comprehensive review of acrivastine pharmacology and clinical efficacy; 8 mg TDS shown effective and well tolerated in chronic urticaria and allergic rhinitis; efficacy comparable to clemastine and terfenadine |
| 7530629 | 1994 | Clinical Review | Drugs | Positions non-sedating antihistamines including acrivastine as the mainstay of treatment for chronic idiopathic urticaria; discusses physical urticarias and urticarial vasculitis requiring separate management |
| 8094649 | 1993 | Clinical Review | Dermatologic Clinics | New H1 antihistamines including acrivastine recommended as first-line for urticaria and mild angioedema; pharmacokinetic considerations inform agent selection |
| 1683523 | 1991 | Comparative Study | Annals of Allergy | Acrivastine among second-generation agents reviewed; substantially less sedating, little or no anticholinergic activity, competitive H1 inhibition confirmed; additional anti-allergic mechanisms noted for some agents in class |
| 2568212 | 1989 | Pharmacological Review | Clinical Pharmacy | Chemistry, pharmacokinetics, clinical efficacy, and adverse effects of acrivastine reviewed; identified as a side-chain-reduced metabolite of triprolidine with distinct pharmacokinetic profile |
| 2525847 | 1989 | Drug Review | DICP: Annals of Pharmacotherapy | Comparative review of non-sedating antihistamines; contextualises acrivastine within emerging second-generation class alongside loratadine, terfenadine, and astemizole |
| 1983393 | 1990 | Narrative Review | Drug and Therapeutics Bulletin | Narrative evaluation of three newly available non-sedating antihistamines including acrivastine; prescribing guidance perspective |
UK Market Information
No MHRA marketing authorisations were identified for acrivastine in the current dataset. This is likely to reflect a data collection gap rather than confirmed non-registration. The mechanistic rationale within this Evidence Pack notes prior UK market approval for this indication. Healthcare professionals must verify current status independently via the MHRA product licence register, the BNF (British National Formulary), and the relevant Summary of Product Characteristics (SmPC) before any clinical or formulary decision.
All Predicted Indications — Summary
| Rank | Indication | TxGNN Score | Evidence Level | Recommendation |
|---|---|---|---|---|
| 1 | Allergic Urticaria | 99.99% | L2 | Proceed with Guardrails |
| 2 | Cold Urticaria | 99.95% | L3 | Research Question |
| 3 | Nasal Cavity Disease | 99.89% | L4 | Hold |
| 4 | Acute Laryngopharyngitis | 99.88% | L5 | Hold |
| 5 | Recalcitrant Atopic Dermatitis | 99.66% | L5 | Hold |
| 6 | IgE Responsiveness, Atopic | 99.55% | L5 | Hold |
Rank 2 — Cold Urticaria: Mechanistically plausible. Cold stimuli trigger mast cell histamine release; H1 antagonism targets the terminal effector, though non-histaminergic pathways (PAF, LTC4) may limit efficacy. One controlled double-blind crossover trial (PMID 2901993, n=18) shows acrivastine significantly superior to both cyproheptadine and placebo in reducing weal areas after ice cube challenge. Warrants further investigation as a research question.
Rank 3 — Nasal Cavity Disease: Mechanistically plausible for the allergic rhinitis subtype, but the label is too broad, encompassing infective and structural disease where H1 antagonism has no role. Existing literature (PMID 1715267) documents efficacy in allergic rhinitis but was not captured under this indication label in the current dataset — likely a data-matching artefact.
Rank 4 — Acute Laryngopharyngitis: Primarily infective (viral or Group A Streptococcal) aetiology; H1 antagonism is not a meaningful therapeutic intervention. Prediction likely reflects topological proximity in the knowledge graph rather than a genuine biological mechanism. Hold.
Rank 5 — Recalcitrant Atopic Dermatitis: Core pathology involves Th2/Th17 immune dysregulation and skin barrier dysfunction; “recalcitrant” by definition implies inadequate response to standard treatment including antihistamines. Dupilumab and JAK inhibitors represent appropriate therapeutic targets. Hold.
Rank 6 — IgE Responsiveness, Atopic: A phenotypic descriptor (high-IgE atopic constitution) rather than a distinct disease entity. H1 antagonism blocks downstream histamine effects but does not modulate IgE production — that requires anti-IgE agents (omalizumab) or IL-4/IL-13 axis intervention. High prediction score reflects knowledge graph topological relationships rather than therapeutic feasibility. Hold.
Safety Considerations
Please refer to the SmPC and BNF for full safety information. Report suspected adverse reactions via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Multiple published reviews and at least one double-blind randomised placebo-controlled trial support the efficacy of acrivastine in allergic urticaria through direct, well-characterised H1 receptor antagonism. The TxGNN prediction score of 99.99% is fully consistent with this established pharmacological evidence base. The principal limitations are the age of the supporting literature (all pre-2002), the absence of any registered clinical trials, and unresolved UK regulatory data.
To proceed, the following is needed:
- Verify current MHRA marketing authorisation status via the MHRA product licence register and BNF; resolve the discrepancy between the dataset’s “not marketed” status and the stated UK regulatory precedent in the mechanistic rationale
- Obtain and review the full SmPC to confirm current dosing recommendations, contraindications, special warnings (including renal impairment, pregnancy, lactation), and drug interactions
- Review the Yellow Card Scheme for any post-marketing safety signals identified since initial authorisation
- Assess whether updated comparative clinical trial data (post-2001) is available to benchmark efficacy against current standard-of-care antihistamines (cetirizine, loratadine, fexofenadine) per BSACI and NICE guidance
- Clarify supply chain and formulary availability before any prescribing or commissioning decision
This report is generated for research reference only and does not constitute medical advice. Drug repurposing candidates require clinical validation before therapeutic application. All prescribing decisions must be made by qualified healthcare professionals in accordance with current UK clinical guidelines, MHRA authorisations, and individual patient assessment.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.